Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Bad
|
New words:
activin, acumen, ADC, ADT, alleviate, androgen, antigen, Avenue, banc, Belgium, Biogen, bomedemstat, Cantonal, carcinogenic, carcinogenicity, Cardiology, caregiving, Carolina, ceiling, CEO, Chirfi, circular, Clalit, College, Colombia, Colorado, Columbia, Connecticut, Conrad, contested, counting, creation, curiam, cytochrome, deadline, demethylase, deployment, derazantinib, diligently, disagree, domain, donating, donation, elderly, en, endocrine, Energize, engineered, facie, faster, fc, FCPA, Finnish, flextime, fluidly, fuel, Glenmark, Greece, Guindo, hardship, HRSA, humanitarian, hyaluronidase, hybrid, IB, IIIA, Imago, incidence, intervene, invaded, invited, involuntary, Israel, JiXing, job, Joseph, kind, Lagevrio, Lincoln, longest, lymphatic, Macau, macro, mainland, marrow, Mectizan, menu, metformin, metric, mice, MMWR, multicomponent, multilateral, myeloproliferative, Natco, natriuretic, neglected, NEJM, newer, nitrosamine, node, North, NTTP, Orion, orna, orthostatic, outmoded, overcharging, overhead, Oxford, PANORAMIC, Pedcev, peptide, phosphodiesterase, pioneering, Playbook, PMBLC, polycythemia, preclinical, prednisolone, prednisone, prima, purported, radiographic, Ratio, reassessment, reconciling, rehearing, relief, RNA, robust, Romanelli, running, SBTi, schizophrenia, Schneider, session, shape, shorter, Sichuan, signatory, sorafenib, STELLAR, steroid, stored, successor, summer, switch, symptom, tachycardia, Taiwan, telework, thrive, thrombocythemia, tool, trace, transgenic, trebling, trophoblast, tropical, uncovering, undergone, underserved, unlawful, unlocking, unnamed, untreated, upheld, upholding, vera, walk, waning, winning, wrote, younger
Removed:
affirmed, Albrecht, ALK, allocating, Antelliq, appellate, aprepitant, arbitrability, attack, bilateral, borrowed, Brexit, causation, clarify, compel, concluding, County, CPS, curable, detailed, divestiture, EGFR, Emend, employing, enhance, estimating, executing, expression, femur, fight, finalized, Fosamax, fracture, Frazier, freedom, Galloping, genomic, genotype, Gerberding, granting, GT, guard, Hill, hormonal, immunotherapy, improving, incorrectly, India, inoperable, institute, intraperiod, IOmet, Julie, jury, Kenneth, label, lapse, leader, left, Los, match, MCC, Mexico, modernize, movement, nausea, notice, package, partnered, Peloton, platinum, plexiform, predominantly, preempted, preemption, PROfound, proposed, question, reconsider, referenced, referendum, remanding, reorganization, repay, reprioritization, requirement, resiliency, reversing, Road, simplify, skin, somatic, Southern, speed, spent, SPRINT, Station, Stratum, Supreme, susceptible, toll, Turkey, VICTORIA, vivo, vomiting, Whitehouse, Zepatier
Filing tables
Filing exhibits
- 10-K Annual report
- 10.7 EXHIBIT-10.7 2017 Annual Nqso Terms and Conditions
- 10.8 EXHIBIT-10.8 2019 Annual Nqso Terms and Conditions
- 10.13 EXHIBIT-10.13 Us Separation Benefits Plan As of 1/1/19
- 10.23 EXHIBIT-10.23 2019 Annual CEO Nqso Terms and Conditions
- 10.24 EXHIBIT-10.24 2019 Annual Rsu Terms and Conditions
- 10.25 EXHIBIT-10.25 2020 Annual Nqso Terms and Conditions
- 10.26 EXHIBIT-10.26 2020 Annual CEO Nqso Terms and Conditions
- 10.27 EXHIBIT-10.27 2020 Annual Rsu Terms and Conditions
- 10.28 EXHIBIT-10.28 2020 Annual Psu Terms and Conditions
- 10.29 EXHIBIT-10.29 2020 Annual CEO Psu Terms and Conditions
- 10.30 EXHIBIT-10.30 2021 Annual CEO Nqso Terms and Conditions
- 10.31 EXHIBIT-10.31 2021 Annual Psu Terms and Conditions
- 10.32 EXHIBIT-10.32 2021 Annual CEO Psu Terms and Conditions
- 10.33 EXHIBIT-10.33 2021 Special Retention Rsu Terms and Conditions
- 10.34 EXHIBIT-10.34 2022 Executive Chairman Rsu Terms and Conditions
- 10.35 EXHIBIT-10.35 2022 Annual Rsu Terms and Conditions (Guindo)
- 10.36 EXHIBIT-10.36 2022 Annual Psu Terms and Conditions (Guindo)
- 10.37 EXHIBIT-10.37 Offer Letter (Guindo)
- 21 EXHIBIT-21 Subsidiary List
- 23 EXHIBIT-23 Consent of Independent Registered Public Accounting Firm
- 24.1 EXHIBIT-24.1 Power of Attorney
- 24.2 EXHIBIT-24.2 Certification of Board Resolution
- 31.1 EXHIBIT-31.1 Rule 13A-14(A)/15D-14(A) Certification of CEO
- 31.2 EXHIBIT-31.2 Rule 13A-14(A)/15D-14(A) Certification of CFO
- 32.1 EXHIBIT-32.1 Section 1350 Certification of CEO
- 32.2 EXHIBIT-32.2 Section 1350 Certification of CFO
- Download Excel data file
- View Excel data file
Related press release
Associated MRK transcripts
MRK similar filings
Filing view
External links
Exhibit 32.2
Section 1350
Certification of Chief Financial Officer
Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: February 24, 2023 | /s/ Caroline Litchfield | |||||||
Name: CAROLINE LITCHFIELD | ||||||||
Title: Executive Vice President, Chief Financial Officer |